
## Llewellyn Mills

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4942712/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal, 2020, 17, 37.	3.2	72
2	Nabiximols for the Treatment of Cannabis Dependence. JAMA Internal Medicine, 2019, 179, 1242.	5.1	68
3	Opioid agonist treatment and patient outcomes during the <scp>COVID</scp> â€19 pandemic in south east Sydney, Australia. Drug and Alcohol Review, 2022, 41, 1009-1019.	2.1	25
4	Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. Accident Analysis and Prevention, 2020, 148, 105784.	5.7	24
5	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence, 2020, 215, 108220.	3.2	19
6	Placebo caffeine reduces withdrawal in abstinent coffee drinkers. Journal of Psychopharmacology, 2016, 30, 388-394.	4.0	15
7	Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. Drug and Alcohol Review, 2020, 39, 441-446.	2.1	15
8	Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history. European Journal of Human Genetics, 2018, 26, 972-983.	2.8	12
9	Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review, 2022, 41, 1095-1108.	2.1	11
10	Assessing the concurrent validity, interâ€rater reliability and test–reâ€test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. Addiction, 2021, 116, 1245-1255.	3.3	9
11	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review, 2020, 39, 356-364.	2.1	7
12	The effect of dose expectancies on caffeine withdrawal symptoms during tapered dose reduction. Journal of Psychopharmacology, 2019, 33, 994-1002.	4.0	6
13	A cluster randomized controlled trial of an online psychoeducational intervention for people with a family history of depression. BMC Psychiatry, 2019, 19, 29.	2.6	6
14	Effect of Genetic Information and Information About Caffeine Content on Caffeine Withdrawal Symptoms. Scientific Reports, 2017, 7, 8407.	3.3	5
15	Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review, 2021, , .	2.1	4
16	Psychometric validation of the Anticipated Effects of Alcohol Mixed with Energy Drinks Scale Psychological Assessment, 2017, 29, 1505-1516.	1.5	3
17	The Essential Network (TEN): Protocol for an Implementation Study of a Digital-First Mental Health Solution for Australian Health Care Workers During COVID-19. JMIR Research Protocols, 2022, 11, e34601.	1.0	1
18	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence, 2022, 234, 109388.	3.2	1

#	Article	IF	CITATIONS
19	The Overdose Response with Take Home Naloxone ( <scp>ORTHN</scp> ) project: Evaluation of health worker training, attitudes and perceptions. Drug and Alcohol Review, 2022, 41, 1085-1094.	2.1	1